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Summary
 
CC chemokine receptor 1 (CCR1) is expressed in neutrophils, monocytes, lymphocytes, and
eosinophils, and binds the leukocyte chemoattractant and hematopoiesis regulator macrophage in-
flammatory protein (MIP)-1
 
a
 
, as well as several related CC chemokines. Four other CCR sub-
types are known; their leukocyte and chemokine specificities overlap with, but are not identical to,
CCR1, suggesting that CCR1 has both redundant and specific biologic roles. To test this, we
have developed CCR1-deficient mice (
 
2
 
/
 
2
 
) by targeted gene disruption. Although the distribu-
tion of mature leukocytes was normal, steady state and induced trafficking and proliferation of
myeloid progenitor cells were disordered in 
 
2
 
/
 
2
 
 mice. Moreover, mature neutrophils from
 
2
 
/
 
2
 
 mice failed to chemotax in vitro and failed to mobilize into peripheral blood in vivo in
response to MIP-1
 
a
 
. Consistent with this, 
 
2
 
/
 
2
 
 mice had accelerated mortality when chal-
lenged with 
 
Aspergillus fumigatus
 
, a fungus controlled principally by neutrophils. To test the role
of CCR1 in granuloma formation, we injected 
 
Schistosoma mansoni
 
 eggs intravenously, and ob-
served a 40% reduction in the size of lung granulomas in 
 
2
 
/
 
2
 
 mice compared to 
 
1
 
/
 
1
 
 litter-
mates. This was associated with increased interferon-
 
g
 
 and decreased interleukin-4 production
in 
 
2
 
/
 
2
 
 versus 
 
1
 
/
 
1
 
 lung lymph node cells stimulated with egg-specific antigen, suggesting
that CCR1 influences the inflammatory response not only through direct effects on leukocyte
chemotaxis, but also through effects on the type 1–type 2 cytokine balance. Thus CCR1 has
nonredundant functions in hematopoiesis, host defense, and inflammation.
 
C
 
hemokines form a large family of secreted proteins
 
z
 
70–80 amino acids in length that regulate multiple
aspects of host defense and inflammation, including angio-
genesis, hematopoiesis, and leukocyte chemotaxis (1–6). The
 
z
 
30 chemokines that are known can be divided roughly
evenly into two major groups, CXC and CC, based on the
presence (CXC) or absence (CC) of a single amino acid
between the first two of four conserved cysteines. CXC
chemokines mainly target neutrophils and T cells, whereas
CC chemokines target monocytes, eosinophils, basophils,
and lymphocytes with variable selectivity, but usually do
not target neutrophils.
Chemokines activate leukocytes by binding to seven trans-
membrane receptors coupled to G
 
i
 
-type G proteins (7).
The twelve receptor subtypes identified so far can be di-
vided into two major groups, given the root names CXCR
and CCR, based on specificity for the two major classes of
chemokines. Most chemokine receptors bind more than
one chemokine, and most chemokines bind to more than
one receptor. The receptors are differentially expressed in
leukocytes, but the specific patterns of expression overlap
considerably.
Gene targeting in mice may be useful for defining spe-
cific biological roles for chemokines and chemokine recep-
tors. Using this technique, Cacalano et al. confirmed a role
for CXCR2 in neutrophil-mediated acute inflammation (8,
9), which had been suspected based on the preferential ex-
pression of CXCR2 in neutrophils (10) and the potent
neutrophil chemoattractant activity of CXCR2 ligands
(11). They also identified an unexpected role for CXCR2
in negative regulation of hematopoiesis (12).
In the present study, we describe mice lacking CCR1
(13–17). CCR1 is constitutively expressed in neutrophils,
monocytes, eosinophils, and T and B lymphocytes (13–19),
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and its principal agonists are macrophage inflammatory protein
(MIP)-1
 
a
 
, reduced on activation normal T expressed and se-
creted (RANTES), and monocyte chemoattractant protein 3
(13, 14, 20). CCR2-5 share at least one agonist and at least
one leukocyte subset with CCR1 (20–24). MIP-1
 
a
 
 has
been implicated in both schistosome egg–induced granulo-
matous inflammation and experimental allergic encephalo-
myelitis by in vivo neutralization studies in mice, and in vi-
rally induced inflammation by challenges of gene-targeted
mice (25–27). MIP-1
 
a
 
 also has complex effects on hema-
topoiesis, acting as a negative regulator of stem and im-
mature progenitor cell proliferation (3–6, 28–30), and as a
positive regulator of lineage-committed progenitor cell pro-
liferation (30, 31). The in vivo actions of RANTES and
monocyte chemoattractant protein 3 have not been studied
in as much detail.
Our results indicate that CCR1 deficiency is benign in
animals raised undisturbed in specific pathogen-free envi-
ronments, but that a variety of defects in both innate and
acquired immunity can be observed under stressed condi-
tions.
 
Materials and Methods
 
Gene Targeting in Embryonic Stem Cells and Generation of Mice.
 
The cloning of the CCR1 gene from a 129/Sv mouse genomic
library has been described previously (15). A 6-kb XbaI fragment
was cloned into Bluescript. A 352-bp EcoRI–HindIII fragment
in the intronless open reading frame (ORF) was replaced by a
1.1-kb neomycin resistance cassette (
 
neo
 
R
 
)
 
1
 
 in the same orienta-
tion. A 6.2-kb fragment of the resulting insert was excised by diges-
tion of a NotI site in the polylinker at the 3
 
9
 
 end and a KpnI site at
the 5
 
9
 
 end from the ORF, and subcloned between the NotI and
KpnI sites of the plasmid pPNT, which contains the HSV thymi-
dine kinase gene. The resulting construct contained 1.3 and 3.8
kb of CCR1 sequence 5
 
9
 
 and 3
 
9
 
 from 
 
neo
 
R
 
, respectively, as shown
in Fig. 1 
 
a.
 
 The construct was linearized with XbaI, and 25 
 
m
 
g
DNA was electroporated into 10
 
7
 
 embryonic stem cells of the J1
cell line. 162 clones resistant to G418, 350 
 
m
 
g/ml of media, and
gancyclovir 2 
 
m
 
M were selected and expanded on feeder layer
cells in 24-well plates. Two homologous recombinants were
identified by Southern blot hybridization of genomic DNA di-
gested with XbaI and hybridized with the probe outside of the
construct, indicated in Fig. 1. Nine chimeric mice were produced
either by microinjection into or aggregation with C57Bl/6 blas-
tocysts according to standard methods (32, 33). Chimeric mice
were mated with wild-type C57BL/6 mice to produce heterozy-
gous mice. Littermates from the mating of heterozygous mice
were then analyzed.
 
Isolation of Mouse Leukocytes.
 
Total leukocytes (80–85% mono-
nuclear cells and 15–20% neutrophils) were isolated from citrated
peripheral blood obtained from mouse tails; erythrocytes were lysed
in lysis buffer (ACK; BioWhittaker, Walkersville, MD). To ob-
tain enriched populations of neutrophils and macrophages, the
peritoneal cavity was washed with PBS 3 or 72 h, respectively, af-
ter peritoneal injection with thioglycollate. The purity of both
populations was 
 
.
 
90% as assessed by light microscopy of Diff-
quick–stained cytospin preparations.
 
Analysis of Progenitor Cells.
 
Unseparated marrow, spleen, and
low density blood leukocytes (retrieved after density cut at 1.070
g/cm
 
3
 
 on Ficoll-Hypaque) were plated at 2 
 
3
 
 10
 
4
 
, 4 
 
3
 
 10
 
5
 
, and
1 
 
3
 
 10
 
5
 
 cells/ml, respectively, in 1% methylcellulose culture me-
dium with 1 U/ml recombinant human Epo, 5% vol/vol poke-
weed mitogen mouse spleen cell conditioned medium, 50 ng/ml
recombinant murine steel factor, and 0.1 mM hemin. Colonies
were scored after 7 d incubation in a humidified environment at
5% CO
 
2
 
 and 5% O
 
2
 
, and absolute numbers of progenitors calcu-
lated based on nucleated cellularity per organ and colony counts
(28, 29). The percentage progenitors in S phase of the cell cycle,
an indication of the proliferative status of cells, was determined by
the high specific activity tritiated thymidine kill assay described
previously (28, 29).
 
[Ca
 
2
 
1
 
]
 
i
 
 Measurements.
 
Cells (10
 
7
 
/ml) were loaded with FURA-2
(Molecular Probes, Eugene, OR) as previously described (34). 2 
 
3
 
10
 
6
 
 cells in 2 ml HBSS were placed in a continuously stirred cu-
vette at 37
 
8
 
C in a fluorimeter (Photon Technology Inc., South
Brunswick, NJ). The data are presented as the relative ratio of flu-
orescence excited alternately at 340 and 380 nm every 0.5 sec,
monitored at 510 nm in response to recombinant mouse MIP-1
 
a
 
(Peprotech, Rocky Hill, NJ) or fMet-Leu-Phe (Sigma Chemical
Co., St. Louis, MO).
 
Chemotaxis.
 
Chemotaxis was analyzed using polyvinylpyr-
rolidone-free polycarbonate membranes with 3-
 
m
 
m pores in 48-
well chambers (Neuro Probe, Cabin John, MD). Mouse MIP-1
 
a
 
in HBSS was placed in the lower chamber, and 150,000 periph-
eral blood leukocytes suspended in HBSS were placed in the up-
per chamber. After incubation for 45 min at 37
 
8
 
C, the membrane
was removed, washed on the upper side with PBS, fixed, and
stained. Cells were counted in five randomly selected fields at
1,000-fold magnification. The pore size was chosen to allow mi-
gration of neutrophils, but not monocytes. Chemotaxis of thio-
glycollate-elicited peritoneal macrophages were tested using a fil-
ter with 8-
 
m
 
m pores.
 
Neutrophil Mobilization to Peripheral Blood.
 
Mice were injected
subcutaneously with 100 
 
m
 
g/kg of the BB10010 variant of hu-
man MIP-1
 
a
 
 (a gift of L. Czaplewski, British Biotech Ltd., Ox-
ford, U.K.). BB10010, human MIP-1
 
a
 
, and mouse MIP-1
 
a
 
 all
have similar selectivity for mouse CCR1 (Gao, J.-L., and P.M.
Murphy, unpublished observations). Complete peripheral blood
leukocyte counts and differentials were determined for tail vein
collections taken before injection and 1 h after injection.
 
Challenge with Aspergillus fumigatus. Aspergillus fumigatus
 
 strains
were grown on minimal media containing 10 mM NaNO
 
3
 
, 1%
glucose, salts, and trace elements for 10 d at 37
 
8
 
C. Conidia were
washed off with 0.1 M potassium phosphate buffer (pH 7.0) con-
taining 0.01% Tween 80. This suspension was washed twice with
0.9% NaCl and further diluted with 0.9% NaCl to a final inocu-
lum size of 2.5 
 
3
 
 10
 
7
 
 conidia/ml, as determined by cell counting
in a hemocytometer. Mice were infected by injecting 0.2 ml of a
suspension containing 5 
 
3
 
 10
 
6
 
 conidia (the LD
 
50
 
 in these experi-
ments) into the lateral tail vein. Animals were then observed for
mortality daily. For the preparation of histologic sections, 10
 
7
 
spores were injected into CCR1 
 
1
 
/
 
1
 
 mice and CCR1 
 
2
 
/
 
2
 
 lit-
termates intravenously, and dying mice were killed 24 and 72 h
after injection. Sections were prepared from lung, kidney, liver,
 
1
 
Abbreviations used in this paper:
 
 BFU-E, erythroid burst-forming unit;
CFU-GEMM, granulocyte, erythrocyte, macrophage, megakaryocyte
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R
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and brain, and stained with hematoxylin and eosin as well as with
Gomori methenamine.
 
Induction of Pulmonary Granulomas.
 
The induction of synchro-
nous egg-induced granulomas was performed as described (35). In
brief, 
 
Schistosoma mansoni
 
 eggs were isolated from the livers of in-
fected mice and enriched for mature eggs (BioMedical Research
Instrs., Rockville, MD). To induce granulomas, mice were in-
jected intravenously with 5,000 eggs. Confirmation of emboliza-
tion of eggs was performed in all mice by histological examination
of the lungs. For histopathological morphometry of granulomas,
the left lung was inflated with and fixed in Bouin-Hollande solu-
tion and processed routinely. The size of the pulmonary granu-
lomas was determined in histological sections stained by a modifi-
cation of the Dominici stain. The diameters of each reaction
containing a single egg were measured in each lung with an ocu-
lar micrometer. Approximately 30 granulomas were counted in
each lung.
 
Cytokine Assays.
 
Single cell suspensions of lung-associated
lymph nodes were prepared aseptically at various times after in-
jection of schistosome eggs. Lung-associated lymph nodes were
pooled from 4 to 5 animals. Cells were plated in 24-well tissue
culture plates at a final concentration of 3 
 
3
 
 10
 
6
 
 cell/ml in RPMI
with 2 mM glutamine, 25 mM Hepes, 10% FBS, 50 
 
m
 
M 2-ME,
penicillin, and streptomycin. Cultures were incubated at 37
 
8
 
C in
5% CO
 
2
 
. Cells were stimulated with schistosome egg antigen at
20 
 
m
 
g/ml. Supernatant fluids were harvested at 72 h and assayed
for cytokine activity. IFN-
 
g was measured by specific two-site
ELISA as previously described. IL-4 levels were determined by
proliferation of CT4S cells. Cytokine levels were calculated using
standard curves constructed using recombinant murine cytokines.
Results
Development of Mice Lacking CCR1. To inactivate CCR1,
we replaced a 352-bp HindIII–EcoRI fragment of the
ORF with a neoR by homologous recombination in 129/Sv
embryonic stem cells (Fig. 1 a); this corresponds to 33% of
the protein from the third to the fifth transmembrane seg-
ment. Chimeric mice were made by injecting targeted
129/Sv cell lines into blastocysts from C57Bl/6 mice. The
chimeric mice were then mated with C57Bl/6 mice to es-
tablish heterozygotes, which were interbred to produce
CCR1 1/1, 1/2, and 2/2 litter mates. Genotypes
were determined by diagnostic XbaI restriction fragment
length polymorphisms of genomic DNA (Fig. 1 b). Mutant
CCR1 mRNA was detected in neutrophils from 1/2 and
2/2, but not 1/1 mice, whereas normal CCR1 mRNA
was detected in neutrophils from 1/2 and 1/1, but not
2/2 mice (Fig. 1 c).
CCR1 genotypic frequencies for 423 total progeny of 12
1/2 mating pairs were: 28% 1/1, 51% 1/2, and 21%
2/2, which is similar to Mendelian expectation for an au-
tosomal gene. CCR1 2/2 mice were viable and fertile,
and exhibited normal growth, development, anatomy and
behavior compared to 1/1 littermates. They have been
observed for up to 20 mo of age, and have not exhibited
defects in hemostasis or healing of tail wounds, or increased
susceptibility to spontaneous infection in a specific patho-
gen-free environment. No significant differences in the his-
tology of bone marrow, lymph node, spleen, or thymus, or
of the complete blood count and differential were observed
between CCR1 2/2 mice and CCR1 1/1 littermates.
Moreover, FACSÒ immunophenotyping of leukocytes from
spleen, lymph node, and peripheral blood of CCR1 2/2
mice using mAbs directed against the neutrophil marker
GR-1, the monocyte marker Mac-1, the T cell receptor,
and the B cell marker B-220 gave similar patterns for
CCR1 2/2 and 1/1 littermates (at least three animals
tested for each genotype for each site; data not shown).
Role of CCR1 in Progenitor Cell Proliferation and Mobiliza-
tion. Selected chemokines, including MIP-1a, have been
implicated in regulation of myeloid stem and progenitor
cell proliferation in vitro (3–5, 30, 31) and in vivo (3, 6, 28,
29), and in mobilization of stem cells and progenitor cells
from bone marrow to blood (6, 36), but underlying mech-
anisms, including the receptors involved, are not known.
Since CCR1 is one of the receptors that binds MIP-1a,
CCR1 2/2 mice were assessed in comparison with CCR1
1/1 littermates for absolute numbers of granulocyte-macro-
phage (granulocyte/macrophage CFU; CFU-GM), eryth-
roid (erythroid burst-forming unit; BFU-E), and multipo-
tential (granulocyte, erythrocyte, macrophage, megakaryocyte
CFU; CFU-GEMM) progenitors in the marrow, spleen,
and blood (Table 1). Although there were no differences in
absolute numbers of progenitors per femur between these
mice, significantly decreased numbers of CFU-GM and
CFU-GEMM were noted in the spleen and circulating
blood of the CCR1 2/2, compared to 1/1 mice. BFU-E
in the spleen and blood of CCR 2/2 mice were also de-
creased, but these differences did not reach statistical signif-
icance.
To test this further, we challenged mice with bacterial li-
popolysaccharide (lps), which is known to perturb my-
elopoiesis and to mobilize progenitors from marrow to the
spleen and blood of rodents (37). Lps induced a significant
Figure 1. Genetic inactivation of CCR1 in mice. (a) Mutagenesis strat-
egy. neoR replaced 352 bp of the ORF and was used to select for targeted
events. The HSV thymidine kinase gene (HSV-tk) was used for coun-
terselection of nontargeted events. (b) Genotypic analysis of tail DNA de-
rived from progeny of heterozygous crosses. The mutated allele (6.7-kb
XbaI fragment) is distinguished from the endogenous allele (6.0-kb XbaI
fragment) using the probe indicated in a. X, XbaI; E, EcoRI; H, HindIII;
K, KpnI. (c) Northern blot analysis of total RNA (10 mg/lane) from TP
neutrophils from mice with the CCR1 genotype indicated at the top of
each lane. The same blot was probed sequentially with an EcoRI–HindIII
fragment of the CCR1 ORF (EH fragment), neoR, and actin, as indicated
to the right of each panel.1962 Phenotype of CC Chemokine Receptor 1–deficient Mice
Table 1. Distribution of Myeloid Progenitor Cells in CCR1 1/1 and 2/2 Mice
Tissue
Genotype
Nucleated Cells
(3 1026)
No. of Progenitors (3 1023/femur or spleen, or 3 1/ml blood)
CFU-GM BFU-E CFU-GEMM
Femur
1/1 22.8 6 1.5 60.7 6 6.1 13.7 6 1.5 2.8 6 0.4
2/2 22.0 6 1.5 50.6 6 4.6 11.7 6 0.9 3.0 6 0.3
Spleen
1/1 110.8 6 7.5 7.7 6 1.1 6.8 6 1.2 0.9 6 0.2
2/2 97.0 6 8.2 4.2 6 0.6* 4.7 6 1.0 0.5 6 0.1‡
Blood
1/1 1.9 6 0.5 203 6 64 109 6 50 24 6 10
2/2 1.6 6 0.3 71 6 28§ 61 6 25 6 6 2i
Results are the mean 6 SEM for a total of eight mice from two separate experiments in which each mouse was assessed individually. Statistical sig-
nificance using Student’s t test for 1/1 versus 2/2 mice in each category: *P ,0.005; ‡P ,0.02; §P ,0.04; iP ,0.05. Differences in other catego-
ries: P .0.05.
Table 2. Disordered Myeloid Progenitor Cell Trafficking in CCR1 2/2 Mice
Tissue
Genotype Challenge
No. of Progenitors (3 1023/femur or spleen, or 3 1/ml blood)
CFU-GM BFU-E CFU-GEMM
Femur
1/1 Diluent 70.6 6 8.6 15.3 6 2.6 2.9 6 0.7
1/1 lps 17.8 6 2.6 (2 75)§ 6.4 6 0.7 (2 58)‡ 1.1 6 0.2 (2 62)*
2/2 Diluent 56.9 6 6.8 13.0 6 0.6 3.2 6 0.6
2/2 lps 14.3 6 1.8 (2 75)‡ 5.7 6 0.6 (2 56)‡ 0.7 6 0.2 (2 78)‡
Spleen
1/1 Diluent 8.2 6 2.2 9.1 6 1.7 0.9 6 0.3
1/1 lps 21.6 6 7.8 (1 163)* 12.6 6 4.1 (1 38) 1.2 6 0.5 (1 33)
2/2 Diluent 4.3 6 1.0 5.6 6 0.8 0.4 6 0.1
2/2 lps 4.2 6 1.1 (2 2) 3.3 6 0.9 (2 41)* 0.2 6 0.03 (2 50)‡
Blood
1/1 Diluent 313 6 101 198 6 78 42 6 15
1/1 lps 705 6 213 (1 125)* 203 6 70 (1 3) 50 6 6 (1 19)
2/2 Diluent 129 6 39 113 6 34 10 6 3
2/2 lps 327 6 141 (1 153)* 144 6 68 (1 27) 17 6 11 (1 70)
Mice were injected intraperitoneally with control diluent or 10 mg E. coli lps once daily for 2 d, and killed 24 h after the last injection. Unseparated
marrow and spleen cells and low density blood cells were set up in colony assays as described in Materials and Methods, and absolute numbers of pro-
genitors per organ were calculated based on nucleated cellularity and colony counts. Results are mean 6 SEM for one experiment with four mice
per group in which each mouse was assessed individually. Numbers in parentheses denote percent change in lps versus control diluent-treated mice
for either 1/1 or 2/2 mice. Significant differences by Student’s t test for lps versus control diluent: *P ,0.05; ‡P ,0.01; §P ,0.001.
decrease in the numbers of CFU-GM, BFU-E, and CFU-
GEMM in marrow from both CCR1 1/1 and 2/2
mice, suggesting that CCR1 is not required for egress (Ta-
ble 2). However, the normal complementary increase in
progenitor cell numbers observed in spleens of lps-chal-
lenged 1/1 mice, which was significant and greatest for
CFU-GM, was absent in spleens from 2/2 mice; in fact,
BFU-E and CFU-GEMM numbers were actually signifi-
cantly decreased. This correlated with a greater lps-stimu-
lated increase of progenitors in the blood of 2/2 mice
compared to 1/1 mice.
We also assessed the proliferative status of myeloid
progenitors in the marrow and spleen of CCR1 2/2 and
1/1 mice under steady-state and lps-perturbed conditions.1963 Gao et al.
Under steady-state conditions (mice given control diluent),
progenitors were proliferating in the marrow as determined
by the percentage in S phase, whereas progenitors in the
spleen were in a slow or noncycling state (compare espe-
cially CFU-GM and CFU-GEMM). In CCR1 1/1 and
2/2 mice not given lps, no significant differences in cy-
cling rates were observed for any progenitor subtype in ei-
ther marrow or spleen (Fig. 2). However, significant differ-
ences were found in progenitor cell proliferation after lps
administration to the mice. This was evident in the spleen,
but not marrow, where lps induced a rapid proliferation of
progenitors in CCR1 1/1, but not in CCR1 2/2 mice.
Thus, CCR1 may regulate both steady-state and induced
movement during adult life of myeloid progenitor cells
from marrow to spleen and blood, as well as the resultant
proliferative status of these stimulated cells.
Role of CCR1 in Neutrophil-mediated Host Defense.
With respect to mature leukocyte function, the results of
three separate assays suggested that CCR1 is critical for
MIP-1a–induced responses in neutrophils. First, the nor-
mal MIP-1a–induced calcium flux in thioglycollate-elic-
ited peritoneal (TP) neutrophils from 1/1 mice was ab-
sent in cells from 2/2 mice (Fig. 3 a). Also, in four
separate experiments the normal MIP-1a–induced calcium
flux observed in total peripheral blood-derived leukocytes
from 1/1 mice was not detectable in 2/2 mice (data not
shown). In contrast, a response to MIP-1a was detected in
TP macrophages from 2/2 mice, suggesting compensa-
tion by other MIP-1a receptor subtypes (22, 24). Second,
peripheral blood neutrophils from CCR1 2/2 mice failed
to chemotax in response to MIP-1a in vitro, whereas neu-
trophils from 1/1 mice exhibited a typical bell-shaped
dose-response curve (Fig. 3 b). Consistent with the calcium
flux results, TP macrophages from both CCR1 2/2 and
1/1 mice responded chemotactically to MIP-1a, and the
responses were similar (not shown). Third, neutrophils
failed to mobilize to peripheral blood in 2/2 mice in-
jected subcutaneously with MIP-1a, whereas neutrophil
concentrations were increased zfivefold in 1/1 litter-
mates 1 h after injection, consistent with previous reports
(6; Fig. 3 c).
Since these tests consistently implicated CCR1 in nor-
Figure 2. Disordered myeloid progenitor cell proliferation in CCR1
2/2 mice. The protocol used and mice evaluated were the same as for
Table 2. Significance for 2/2 compared to 1/1 mice given control di-
luent: a, P ,0.05; b, P ,0.005; c, P ,0.001. Significance for 2/2 mice
given lps compared to 1/1 mice given lps: d, P ,0.001.
Figure 3. Loss of MIP-1a–dependent functions in mature neutrophils from CCR1 2/2 mice. (a) Calcium flux response. [Ca21]i was monitored in
real time in FURA-2–loaded leukocytes stimulated with 100 nM mouse MIP-1a and 5 mM fMet-Leu-Phe. Each tracing represents analysis of 3 3 106
cells from a single mouse. Each tracing corresponds to the TP cell type indicated at the top of the column in which it is found and to the CCR1 genotype
indicated at the top left. Agonists were added at the times indicated by the arrows. Results are from a single experiment representative of at least four sep-
arate experiments. (b) Neutrophil chemotaxis. Results are the mean 1/2 SEM of triplicate determinations in a single experiment using peripheral blood
leukocytes and mouse MIP-1a in vitro, and are representative of three separate experiments. There was no difference in fMet-Leu-Phe–induced chemo-
taxis between neutrophils from CCR1 2/2 and 1/1 mice (not shown). (c) Neutrophil mobilization to peripheral blood. Each pair of bars represents
the peripheral blood neutrophil concentration for a single mouse before and 1 h after subcutaneous injection with 2 mg of the BB10010 variant of MIP-1a.
Results are from a single experiment, representative of two separate experiments.1964 Phenotype of CC Chemokine Receptor 1–deficient Mice
mal neutrophil function, we challenged mice intravenously
with A. fumigatus, an opportunistic fungus in patients with
prolonged neutropenia or defects in neutrophil function
(38). In this model, CCR1 2/2 mice exhibited a mark-
edly higher rate and extent of mortality compared to
CCR1  1/1 littermates (Fig. 4). 70% of CCR1 2/2 mice
injected with 5 3 106 spores died by day 15, in contrast to
only 20% in CCR1 1/1 mice during the same period.
Only 30% of CCR1 2/2 mice survived beyond 30 d of
observation, whereas 60% of CCR1 1/1 mice remained
healthy. Fatally infected mice from both groups developed
severe ataxia associated with fungal invasion of the central
nervous system 2–3 d before death. Such symptoms were
observed at least 2–3 d earlier in the 2/2 mice, compared
to CCR1 1/1 littermates. The same pattern of acceler-
ated lethality in CCR1 2/2 mice was observed when the
inoculum was increased to 107 spores. Histological sections
prepared with the organs of mice injected with 107 spores
showed robust hyphal growth in kidney, lung, liver, and
brain 24 h after injection in CCR1 2/2 mice, but were
not detected in brain and lungs of CCR1 1/1 mice until
72 h after injection.
At 24 h, kidney sections from CCR1 2/2 mice showed
multiple foci of fungal growth in both cortex and medulla,
but very little inflammation. Only one fungal fragment and
no inflammation was detected in CCR1 1/1 kidney at
this time point. However, by 72 h, numerous fungal ab-
scesses were observed in both strains of mice. Despite simi-
lar histopathology, the lesions were much more advanced
with more extensive debris in CCR1 2/2 mice, com-
pared to 1/1 mice. Extensive karyorexis of the inflamma-
tory cells was observed, which precluded precise identifica-
tion. At 72 h, both types of mice showed ungerminated,
swollen conidia throughout the liver with no inflamma-
tion. Host response around brain lesions was also unre-
markable. None of the infected organs exhibited hyphal in-
vasion of blood vessels.
Role of CCR1 in Granuloma Formation. In addition to neu-
trophils, CCR1 is expressed by lymphocytes, macrophages,
and eosinophils (14, 17, 19), and we hypothesized that it
may regulate migration of all of them in vivo. Therefore,
we challenged mice by intravenous injection of S. mansoni
eggs, which lodge in the lung and induce formation of
granulomas composed of lymphocytes, macrophages, eosi-
nophils, and neutrophils (39). A second reason for this
challenge was a report that depletion of MIP-1a in mice by
injection of neutralizing mAb results in a reduced granulo-
matous response to schistosome eggs (25). CCR1 2/2
mice consistently developed smaller granulomata than 1/1
littermates, z40% decreased 14 d after primary egg injec-
tion (Fig. 5 a).
This result is consistent with a role for CCR1 in granu-
loma formation through a direct effect on leukocyte chemo-
taxis. Moreover, since there were no obvious differences
in the cellular composition of the granulomas in 2/2 and
1/1 mice, it suggests a possible effect of CCR1 deficiency
on leukocyte extravasation for many leukocyte subtypes in
vivo. However, CCR1 could also be acting indirectly
through effects on cytokines. Numerous studies have
shown that type 2 cytokines (e.g., IL-4 and -10) enhance
egg-induced pulmonary granuloma formation in the schis-
tosome model, whereas type 1 cytokines (e.g., IFN-g and
IL-12) are inhibitory (39). To test whether CCR1 influ-
ences type 1 and type 2 cytokine expression, we killed
mice on days 3, 6, and 14 after egg injection, and analyzed
the draining lung lymph node cells for changes in IFN-g
and IL-4 expression in vitro in response to a soluble mix-
Figure 4. Accelerated lethality
in CCR1 2/2 mice challenged
with A. fumigatus. Mice were in-
jected with 5 3 106 spores in the
tail vein. Results are from a sin-
gle experiment with 2/2 and
1/1 sex-matched littermates
(n  5 10 in each group), repre-
sentative of two separate experi-
ments with a consistent pattern.
Figure 5. Impaired lung gran-
uloma formation and type 1–type
2 cytokine balance in CCR1 2/2
mice. At 2–3 mo of age, sex-
matched CCR1 1/1 and 2/2
littermates were injected intrave-
nously with 5,000 eggs of S.
mansoni. (a) Granuloma forma-
tion. Animals were killed 14 d af-
ter injection, and granuloma size
was determined. Results are the
mean 1/2 SEM of three sepa-
rate experiments, 4–5 animals/
group/experiment, 30 granulo-
mas/animal.  P  ,0.01. (b) type
1–type 2 cytokine balance. Mice
were killed 3, 6, and 14 d after
egg injection. Draining lung
lymph node cells were pooled
and cultured in vitro with medium alone or medium plus SEA 20 mg/ml for 3 d, and cytokine concentrations were then measured in the supernatants.
Each bar represents the mean of 4–5 mice. 1/1, solid bars; 2/2, open bars.1965 Gao et al.
ture of schistosome egg antigen (SEA). Consistent with pre-
vious reports, the SEA-induced cytokine profile for cells
from both 2/2 and 1/1 mice evolved from an early type 1
bias into a later type 2 bias which peaked at a time when
granuloma size was maximal. However, we consistently
observed elevated constitutive as well as SEA-induced ex-
pression of IFN-g in CCR1 2/2 mice compared with 1/1
littermates (Fig. 5 b). Conversely, cells from 2/2 mice
consistently produced less IL-4 in response to SEA at all
time points compared to cells from 1/1 mice. Leukocyte
subset depletion studies suggested that the increase in con-
stitutive production of IFN-g was likely attributable to NK
cells, which is consistent with previous studies of the origin
of IFN-g in this model (data not shown; 39).
Discussion
Our analysis of CCR1 2/2 mice indicates that CCR1
is not required for normal mouse development or for ade-
quate antimicrobial defense when animals are raised undis-
turbed in specific pathogen-free environments. However,
diverse nonredundant roles for CCR1 in immune system
function can be observed when the animals are stressed. In
particular, our experiments implicate CCR1 in migration
of early and later subsets of myeloid progenitor cells from
marrow to spleen and blood after lps injection, and the
subsequent proliferative stimulation of these cells in the
spleen, neutrophil chemotaxis, MIP-1a–induced neutrophil
mobilization, neutrophil-mediated antifungal host defense,
schistosome egg–induced granulomatous inflammation, and
regulation of the type 1–type 2 cytokine balance.
The phenotype of the CCR1 2/2 mouse is analogous
to that previously described by Cook et al. for MIP-1a 2/2
mice created by gene targeting (27). Their mice also appear
phenotypically normal when raised undisturbed in specific
pathogen-free environments, but have impaired inflamma-
tory responses to microbial challenge, specifically with Cox-
sacckie B and influenza viruses. Humans homozygous for
an inherited inactivating mutation of the CCR5 gene (en-
coding a receptor for MIP-1a, MIP-1b, and RANTES) or
the Duffy gene (encoding a receptor for certain CC and
CXC chemokines) have been identified, and they have no
obvious health problems (40–42). On the contrary, in both
cases they appear to be resistant to infectious disease, specif-
ically to HIV-1 in the case of CCR5 deficiency (40, 43–
45), and to the malaria-causing protozoan Plasmodium vivax
in the case of Duffy deficiency (41). In both cases, the
chemokine receptor is needed by the pathogen to enter
target cells (46, 47). The high tolerance of mice for defi-
ciencies in MIP-1a and CCR1 and of humans for defi-
ciencies in CCR5 and Duffy contrasts with the perinatal
lethal phenotype of mice deficient in the CXC chemokine
SDF-1 (48) and the disordered hematopoiesis observed in
mice deficient in CXCR2 (8, 9, 12), and may be a conse-
quence of the higher degree of redundancy found so far for
CC chemokines and their receptors (7). Nevertheless, it is
also clear that MIP-1a and CCR1 are not fully compen-
sated under conditions of intense irritation created in the
challenge experiments.
Fundamental differences in the structure and function of
the chemokine system in mouse and human warrant extra
caution in extrapolating to humans from experimental re-
sults obtained in the mouse. For example, the mouse has an
orthologue of the human IL-8 receptor subtype CXCR2
(49), but counterparts of IL-8 itself and the other known
human IL-8 receptor subtype CXCR1 have not been iden-
tified. Also, RANTES is a poor agonist for mouse CCR1,
but is a potent and effective agonist for human CCR1,
even though RANTES binds to both human and mouse
CCR1 with similar affinity (13–17). In contrast, MIP-1a
(both mouse and human forms) is a high affinity ligand and
potent agonist for both human and mouse CCR1. Further,
mouse and human neutrophils appear to differ in their use
of CCR1. Like mouse neutrophils, human neutrophils ex-
press CCR1, and they respond to its agonists with a cal-
cium flux. However, MIP-1a does not chemoattract hu-
man neutrophils in vitro (50), whereas our data clearly
indicate that it is a potent chemoattractant for mouse neu-
trophils, consistent with earlier reports of the ability of na-
tive MIP-1 to induce neutrophil accumulation at sites of
injection (51). CCR1 may have evolved to play a more
important role in mouse neutrophils than human neutro-
phils to compensate for the apparent absence of CXCR1
on mouse neutrophils. Mouse TCA-3 is another example
of a CC chemokine that chemoattracts mouse neutrophils.
Like MIP-1a, its human homologue, I-309, does not
chemoattract human neutrophils (52). The failure of neu-
trophils from CCR1 2/2 mice to respond to MIP-1a
suggests that CCR1 is the dominant, and perhaps only,
MIP-1a receptor subtype expressed in these cells. More-
over, the data prove that CCR1 is a bona fide chemotactic
receptor.
CCR1 appears to be important for mouse neutrophil-
mediated host defense, since CCR1 2/2 mice are much
more susceptible to infection with A. fumigatus, a ubiqui-
tous fungus that causes invasive and highly lethal infections
in humans and mice mainly when neutrophil number or
function are impaired. The neutrophil is most critical in the
early clearance of the organism (38). Our data showing
large numbers of hyphae in kidney without inflammation
at 24 h after challenge suggest that neutrophils block effi-
cient tissue invasion from the blood, and that this is defi-
cient in CCR1 2/2 mice. The larger abscesses seen in es-
tablished kidney lesions in CCR1 2/2 mice compared to
1/1 littermates indicate that CCR1 is not essential for
maturation of the inflammatory response once hyphal inva-
sion of tissue is established.
Loss of CCR1 function is not apparent in macrophages
and lymphocytes from CCR1 2/2 mice, probably be-
cause other MIP-1a receptor subtypes such as CCR4 and
CCR5 compensate. We have not directly tested the func-
tion of purified eosinophils from CCR1 2/2 mice owing
to difficulties in obtaining sufficient numbers of cells. How-
ever, we have tested the role of CCR1 in eosinophil mi-
gration in vivo in the schistosome egg model of granuloma1966 Phenotype of CC Chemokine Receptor 1–deficient Mice
formation. These granulomas are composed of egg sur-
rounded by a mixed leukocyte infiltrate including neutro-
phils, eosinophils, macrophages, and T lymphocytes. We
consistently observed a marked reduction in granuloma size
in CCR1 2/2 animals compared to CCR1 1/1 litter-
mates, but found no obvious changes in the cellular com-
position of the lesions. Detailed immunophenotyping of
the granuloma cells will be needed to look for more subtle
differences in the cellular composition between CCR1 1/1
and 2/2 mice. Although this result may be a direct effect
of the loss of the chemotactic function of CCR1, our data
also suggest a possible indirect mechanism, through effects
on the type 1–type 2 cytokine balance. It has been estab-
lished that granuloma formation in this model is a function
of the relative levels of type 1 and type 2 cytokines (25, 35,
39). Type 1 cytokines such as IFN-g inhibit and type 2 cy-
tokines such as IL-4 promote granuloma formation. Taken
together, the results suggest a novel mechanism for leuko-
cyte accumulation at sites of inflammation in vivo,
whereby migration is regulated not only by the direct ef-
fects of the chemoattractant on cell motility, but also by its
effects on type 1–type 2 cytokine balance, both mediated
through the same receptor.
Little is known about the movement of hematopoietic
stem and progenitor cells between hematopoietic organs
during fetal development or adult life. Our results support a
role for CCR1 in the trafficking of early and later subsets of
myeloid progenitor cells between marrow and spleen. Un-
der steady state conditions, decreased numbers of progeni-
tors were found in the spleen and blood of CCR1 2/2,
compared to 1/1 mice. Under the stress of lps administra-
tion to mice, the enhanced numbers of progenitors seen
in the spleen of CCR1 1/1 mice were not detected in
the spleen of CCR1 2/2 mice; in fact, a decrease in pro-
genitor numbers was seen in CCR1 2/2 spleen after lps
injection into the mice with increased levels of circulating
progenitors in the blood of CCR1 2/2, compared to 1/1
mice. In the context of migration of progenitors from or-
gan to organ of adult rodents after stress, it is generally con-
sidered that this movement occurs from marrow to spleen
via blood (37). However, the biological relevance of this
phenomenon is not clear. The data in Table 2 for 1/1
mice responding to lps makes it clear that the increase in
splenic progenitors in spleen and blood does not com-
pletely compensate for the loss of progenitors from the
marrow. Thus, there was a loss of 52.8 3 103 CFU-GM,
8.9 3 103 BFU-E, and 1.8 3 103 CFU-GEMM from fe-
murs of 1/1 mice treated with lps. However, the in-
creases noted in the spleens of these mice were 13.4 3 103
CFU-GM, 3.5 3 103 BFU-E, and 0.9 3 103 CFU-
GEMM. The differences between marrow and spleen could
not be accounted for by the progenitors in the blood. What
is happening to the unaccounted for progenitors in 1/1
mice is not known; however, it is clear that lps-induced
events in the spleens of 2/2 mice are different from those
of 1/1 mice. MIP-1a, by itself, is a modest mobilizer of
myeloid stem and progenitor cells from the marrow to
blood (6, 36), but has a synergistic effect when tested with
other cytokines such as G-CSF (6). It remains to be deter-
mined whether CCR1 is involved in MIP-1a–induced
mobilization, alone and in combination with other cytokines.
MIP-1a acts as a negative regulator of hematopoietic
stem and immature progenitor cell proliferation in vitro
and in vivo (3–5, 28–30). It has also been shown to act as
an enhancing cytokine in vitro for the proliferation of more
mature progenitors (30, 31). The enhanced proliferation of
myeloid progenitor cells in the spleens of CCR1 1/1 but
not 2/2 mice after challenge with lps suggests that under
stress, CCR1 acts in a positive regulatory sense for cell pro-
liferation for migration of cycling cells. Further studies will
be necessary to clarify whether MIP-1a mediates its mye-
loid progenitor cell proliferative effects through CCR1
and/or other MIP-1a receptor subtypes.
The finding of nonredundant biological functions for
CCR1 is fairly surprising given the large number of
chemokines and receptors, and their overlapping in vitro
functions. The CCR1 2/2 mouse should be useful for
analyzing additional roles of this receptor in other types of
inflammatory and infectious diseases.
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